Roche Holding AG (RHHVF)
| Market Cap | 350.32B +33.4% |
| Revenue (ttm) | 79.90B +1.5% |
| Net Income | 16.24B +55.6% |
| EPS | 20.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 21.57 |
| Forward PE | 16.74 |
| Dividend | 10.98 (2.50%) |
| Ex-Dividend Date | Mar 27, 2025 |
| Volume | 33,510 |
| Average Volume | 46,616 |
| Open | 448.56 |
| Previous Close | 449.03 |
| Day's Range | 427.74 - 455.49 |
| 52-Week Range | 277.00 - 490.33 |
| Beta | 0.21 |
| RSI | 40.37 |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
2 Underrated Weight Loss Stocks to Buy Now
Regeneron has a pair of weight-loss candidates close to entering late-stage studies. Roche's recent mid-stage readout positions it as a strong contender in the weight loss market.
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche (RHHBY) Diagnostics Division Faces Tariff Challenges
Roche chairman still expects diagnostics hit from US tariffs
Roche expects its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, but its diagnostics division remains exposed and could face renewed duti...
Zealand's stock falls 35% after disappointing drug result. Its CEO tells CNBC people need to focus less on the 'weight loss Olympics'
Zealand and Roche are jointly developing the drug petrelintide which in a mid-stage study led to a worse-than-expected 10.7% weight-loss over 42 weeks.
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Basel, 06 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of the phase III ALLEGORY trial of Gazyva®/Gazyvaro® (obinutuzumab) in adults with systemic lupus ery...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that a detailed analysis of the Phase III ALLEGORY trial of Gazyva® (...
New England Journal of Medicine publishes phase III ALLEGORY data showing Roche's Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus
Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms Gazyva/Gazyvaro has th...
New England Journal of Medicine Publishes Phase III ALLEGORY Data Showing Genentech's Gazyva Significantly Reduces Disease Activity in the Most Common Form of Lupus
Over three quarters of people on Gazyva plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms G azyva has the potential to be...
Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly
Roche and Zealand Pharma's obesity drug petrelintide showed up to 11% weight loss in a Phase 2 trial with strong safety results. ... Full story available on Benzinga.com
Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
The company said the data supported further development of the drug in chronic weight management on its own or in combination with other drugs due to its tolerability.
Roche's Petrelintide Achieves Over 100% Weight Loss In Phase 2 Trial
(RTTNews) - Roche (RHHBY) announced positive topline results from its Phase 2 ZUPREME-1 study of Petrelintide, an investigational amylin analog for people living with overweight and obesity.
Roche's (RHHBY) Genentech Reports Positive Trial Results for Obesity Drug
Roche's (RHHBY) Genentech Reports Positive Trial Results for Obesity Drug
Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial
Genentech, part of Roche , said on Thursday that its experimental obesity drug helped people lose up to 10.7% of their body weight in a mid-stage study.
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive topline results from the Phase II ZUPREME-1 trial evaluating investigational petrelintide versus placebo in 493 peopl...
Genentech Announces Positive Phase II Results for Petrelintide, an Amylin Analog Developed for People Living With Overweight and Obesity
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from the Phase II ZUPREME-1 trial evaluating...
New survey demonstrates how diabetes limits day-to-day freedom for people around the world and highlights need for predictive tools
Global survey of 4,326 people with diabetes shows how the unpredictability and mental burden associated with managing the condition negatively impacts daily life.1 Majority of respondents say that con...
Roche (RHHBY) Targets Top Position in Weight Loss Drug Market
Roche (RHHBY) Targets Top Position in Weight Loss Drug Market
Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports
Swiss pharmaceutical company Roche is aiming for a double-digit market share in the weight loss market and wants to close the gap on its Danish rival Novo Nordisk , its CEO told Germany's Hand...
Roche Multiple Sclerosis Drug Meets Key Goal in Late-Stage Trial
The drugmaker said the results provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for relapsing and primary progressive multiple sclerosis.
Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS ...
[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)
Basel, 02 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful a...
Quantum Strategy's David Roche thinks Iran regime could be 'gone within a year'
David Roche of Quantum Strategy explains why he believes Iran's current regime could fall within a year. He also says he does not see Tehran conceding to U.S. demands to limit its nuclear program, vie...
The Zacks Analyst Blog Highlights Costco Wholesale, Roche, Lam Research, Spruce Power and IDT
Costco, Roche and Lam Research lead Zacks??? top stock reports, with standout gains and resilient fundamentals across sectors.
Roche (RHHBY) Awaits FDA Decision on Giredestrant for Breast Cancer
Roche (RHHBY) Awaits FDA Decision on Giredestrant for Breast Cancer
FDA Approval For AbbVie/AstraZeneca's Combination Treatment Could Set New Standard For Slow Growing Blood Cancer
On Friday, the U.S. Food and Drug Administration (FDA) approved AbbVie Inc.'s (NYSE: ABBV) combination treatment for chronic lymphocytic leukemia (CLL). The FDA has approved the combination of Vencle...